RLAY
Relay Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RLAY
Relay Therapeutics, Inc.
A clinical-stage precision medicine company that develops commercializes small molecule therapies for the treatment of solid tumors cancer
60 Hampshire Street, Cambridge, MA
--
Relay Therapeutics, Inc., was incorporated in Delaware on May 4, 2015. The company is a clinical-stage precision pharmaceutical company dedicated to transforming the drug discovery process, with an initial focus on enhancing small-molecule therapeutic discoveries in targeted oncology. The company is built on unparalleled insight into protein movement and the relationship between this dynamic behavior and protein function. The company's Dynamo platform integrates a range of advanced experimental and computational methods, allowing the company to apply its understanding of protein structure and movement to drug development. The company is developing its lead product candidates RLY-4008 and RLY-1971, and is developing drug candidates for the PI 3Kα Selective Mutant Program (RLY-PI 3K1047 Program) to treat patients with advanced solid tumors.
Company Financials
EPS
RLAY has released its 2025 Q3 earnings. EPS was reported at -0.43, versus the expected -0.42, missing expectations. The chart below visualizes how RLAY has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
